Virbac Stock

Virbac EBIT per Share

The EBIT per Share of Virbac (VIRP.PA) as of Aug 10, 2026 is 25.78 EUR. In the previous year, EBIT per Share was 25.91 EUR — a change of -0.49% (lower).

EBIT per Share

25.78EUR

YoY

-0.49%

Last updated:

EBIT per Share of Virbac is 2026 25.78 EUR. EBIT per Share of Virbac was 2025 25.91 EUR. It decreases by -0.49% lower compared to the previous year.
Access this data via the Eulerpool API

Virbac Stock analysis

What does Virbac do? Virbac SA is a French company specializing in animal medicines and care products. The company was founded in 1968 by Pierre Richard Dick, who studied veterinary medicine at the École nationale vétérinaire d'Alfort and gained experience as a veterinarian. Since its founding, Virbac SA has been headquartered near Carros, France and operates worldwide. The business model of Virbac SA is to offer a wide range of products to veterinarians and pet owners, aiming to ensure optimal health, care, and quality of life for their pets. This includes everything from vaccines, diagnostics, and medications to grooming products that veterinarians and pet owners need to ensure optimal pet healthcare. Virbac SA has five main business areas, namely livestock, pets, horses, hygiene products, and specialties. The livestock sector includes products such as feed additives and antiparasitics tailored to the specific needs of cattle, pigs, poultry, and fish. In the pets sector, Virbac SA offers products specifically tailored to dogs, cats, birds, and other pets. This includes both disease prevention and treatment products. In the horse sector, the company offers products for the maintenance, care, and health of horses. Another division of Virbac SA is hygiene products. The company offers a wide portfolio of products and solutions that support both veterinarians and pet owners in ensuring the health and care of animals. This ranges from infection control products to animal-specific shampoos and grooming items. The specialties sector, on the other hand, includes specialized products such as targeted diagnostics, therapeutics, and dietary supplements. The constant focus on research and development also leads to innovative product launches that consistently meet the highest quality standards. An example of this is the scientifically developed dental hygiene product line that improves both the oral health and breath quality of dogs and cats. For this, Virbac SA also receives awards from the Veterinary Center for Clinical Medicine in Munich. Through a systematic international expansion strategy, Virbac SA is now present in more than 100 countries. The company employs over 4,800 people worldwide and achieved a turnover of 954 million euros in 2019. Overall, Virbac SA stands for consistently high product quality and a strong customer orientation. With a combination of expertise and extensive scientific research and development, particularly in the field of animal health and care, the company is an important player in the global animal medicine manufacturing market. Virbac is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Virbac stock

EBIT per Share of Virbac is 25.78 EUR in 2026.

EBIT per Share of Virbac changed from 25.91 EUR to 25.78 EUR, representing a -0.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Virbac since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

Income Statement — Virbac

All Key Metrics — Virbac